Search company, investor...


Founded Year



Unattributed | Alive

Total Raised


Last Raised

$2.6M | 10 yrs ago

About cerboMed

Cerbomed is a medical device company that focuses on neuromodulation. The company focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

Headquarters Location

Henkestrasse 91



Missing: cerboMed's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: cerboMed's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

cerboMed Patents

cerboMed has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Electrotherapy, Neurotechnology, Ear, Neurophysiology, Auditory system


Application Date


Grant Date



Related Topics

Electrotherapy, Neurotechnology, Ear, Neurophysiology, Auditory system



Latest cerboMed News

Vagus Nerve Stimulator Market Key Players : ElectroCore LivaNova LLC, Cerbomed GmbH, ReShape Lifesciences, Inc., and NERVANA LLC

Apr 20, 2022

Search jobs 20-Apr-2022 Vagus Nerve Stimulator Market Key Players : ElectroCore LivaNova LLC, Cerbomed GmbH, ReShape Lifesciences, Inc., and NERVANA LLC Of the total global population inflicted by neurological disorders, approximately 50% suffers from an epileptic disorder, research and surveys say. Vagus nerve stimulation is witnessing a rapidly expanding applicability beyond epilepsy, in the recent past. Research uncovers potential efficiency of vagus nerve stimulation in the obesity management of depression patients. Positive outcome of vagus nerve stimulation in treatment-resistant depression and epilepsy surgery indicate promising opportunities approaching in the near future. Driven by a paradigm shift from implantables to non/minimally invasive devices, the vagus nerve stimulator (VNS) landscape is gradually encouraging the growth of transcutaneous VNS to be witnessed over the next couple of decades. Moreover, growing R&D efforts in the integration of next-generation technology to bypass the shortcomings of implantable VNS is likely to shape the future of vagus nerve stimulator marketplace. However, currently, implantable vagus nerve stimulator accounts for a whopping share in the revenue of VNS market. As indicated by a newly published intelligence study by Future Market Insights, the global vagus nerve stimulator market is likely to demonstrate robust year on year revenue growth of more than 9% in 2019. To remain ahead of your competitors, request for a sample – Europe Steals the Limelight, Crossing US$ 100 Million Revenue in 2019 North America currently holds a massive revenue share in the vagus nerve stimulator market, and FMi projects continued dominance of this region over other regional markets in comping years. However, the report forecasts emergence of Europe and Asia Pacific (excluding Japan) as highly attractive territories for key market players in the near future. Europe will reportedly cross the US$ 100 million mark in 2019, reflecting the most lucrative opportunities for vagus nerve stimulator manufacturers. “At present, Europe and APEJ hold a collective revenue share of over 40% in market, of which the former is gradually moving towards extending its individual market value share up to 1/4th of the global revenue,” explains a senior research analyst at FMI. Adding further, the analyst says, “Favorable regulatory and reimbursement scenario across Europe and relatively easy availability of VNS systems are most prominently driving the growth of vagus nerve stimulator market in Europe. VNS sales in Europe will also benefit from the strong presence of leading industry manufacturers in the region”. Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – Taxonomical Insights – By Type, Application, and End User By the type of vagus nerve stimulator, implantable stimulator continues to bring in the most of the revenue to market. Epileptic seizures secure the spot of the most sought after application type in vagus nerve stimulator landscape. Hospitals remain the largest end user of vagus nerve stimulator. FMI research indicates that specialty clinics and home care settings are emerging as attractive end user candidates in recent years. Thorough competition analysis of vagus nerve stimulator landscape reveals a few important developmental strategies that are ruling the minds of VNS manufacturers at present. Besides geographical expansion, leading players in vagus nerve stimulator market are focusing on the extension of their existing offerings portfolio, according to the report. In an effort to address the challenges to VNS adoption posed by the high price point, companies are now reassessing their pricing strategies for a competitive advantage. A number of companies are also directing their strategic focus on a stronger distribution network. Strategic partnerships with local and regional distributors and retailers hold immense importance for the competitors in VNS landscape. Long-term contractual collaborations with recognized hospitals, research and pathology laboratories, and CROs are emerging as a growing trend among manufacturers of vagus nerve stimulator. About Future Market Insights (FMI) Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years. Contact Us:

cerboMed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

cerboMed Rank

cerboMed Frequently Asked Questions (FAQ)

  • When was cerboMed founded?

    cerboMed was founded in 2005.

  • What is cerboMed's latest funding round?

    cerboMed's latest funding round is Unattributed.

  • How much did cerboMed raise?

    cerboMed raised a total of $2.6M.

  • Who are the investors of cerboMed?

    Investors of cerboMed include Cyberonics, MIG Verwaltungs, S-REFIT Regionaler Finanzierungsfonds fur Innovationen und Technologieunternehmen, Alfred Wieder, GA Global Asset Fund & KG and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.